Tashkent, Uzbekistan (UzDaily.com) — As part of the official visit of the Uzbek delegation to the People’s Republic of China, a meeting was held with the leadership of Walvax Biotechnology Co., Ltd., one of China’s leading biopharmaceutical companies.

Founded in 2001, Walvax specializes in the development and production of high-quality vaccines. Its portfolio includes nine registered products, such as vaccines against pneumococcal infection (PCV13), human papillomavirus (HPV2), and meningococcal infection. The company’s production facilities are capable of manufacturing up to 390 million doses annually, with products distributed across China and exported to 18 countries.

The meeting was attended by representatives of the Ministry of Health of Uzbekistan, including the head of the department for determining pharmaceutical needs, as well as experts from the Agency for the Development of the Pharmaceutical Industry and the Center for Pharmaceutical Product Safety.

The talks focused on launching local vaccine production in Uzbekistan, technology transfer, product registration on the Uzbek market, and identifying reliable partners for joint projects.

Walvax executives expressed strong interest in establishing sustainable cooperation with Uzbekistan. Key priorities include setting up domestic production, ensuring stable vaccine supply for the national market, and exploring opportunities for expansion into Central Asia and the CIS region.

At the conclusion of the meeting, both parties reaffirmed their commitment to strengthening partnerships and agreed to maintain regular information exchange on strategic areas of collaboration.

The agreements reached are expected to become a significant milestone in the development of Uzbekistan’s pharmaceutical industry and contribute to enhancing the country’s national healthcare system.